Summary The use of molecular biological methodologies has provided a greater understanding of the cytotoxic effects of cisplatin and the underlying mechanisms of tumour cell resistance. Resistance to cisplatin is often multifocal with plasma membrane, cytosolic and nuclear components. Cisplatin-DNA adducts appear to be recognised by specific damage recognition proteins. Proteins associated with the transport of platinum through plasma membranes and genes associated with cisplatin resistance appear to be close to being elucidated. Current Phase I and Phase II clinical trials with platinum-containing complexes largely focus on the 1,2 diaminocyclohexane (DACH) carrier ligand, the dicarboxylatocyclobutane leaving group and complexes which circumvent cisplatin resistance in murine leukaemia models. At present, the trials are at too early a stage to allow comment on their clinical utility and, consequently, the relevance of the murine leukaemiabased preclinical observations. On the horizon, orally active platinum (IV) ammine/amine dicarboxylate dichloride coordination complexes with preclinical toxicological profiles similar to carboplatin should enter clinical trial in the next year. 
The antitumour properties of cisplatin [cis diamminedichloro platinum (II)] were discovered over 20 years ago. The first cancer patient received the drug in 1971. Since then, platinum drug development has proceeded in two broad directions aimed at either modulation of the toxic side effects of the parent drug (particularly nephrotoxicity) or circumvention of cisplatin resistance (both intrinsic and acquired) in tumours. To date, despite numerous synthetic chemistry initiatives, only one additional platinum complex, carboplatin [Paraplatin, cis Figure 2 . Farrell (University of Vermont, Burlington, Vermont, USA) described the synthesis and biological properties of several bis and trans platinum complexes (1 and 2, Figure 2 There were very few reports in the area of non-platinum metal complexes. Ware (University of Auckland, Auckland, New Zealand) described a series of Co (III) complexes designed to release a cytotoxic alkylating agent upon metabolic reduction to Co (II) under hypoxic conditions. Although the possibility exists for intramolecular Nalkylation of the diamine mustards in these complexes upon reduction to Co (II) (which would inactivate the alkylating function) some hypoxia selective cytotoxicity was observed against AA8 Chinese hamster fibroblasts. Several ruthenium (II) DMSO complexes containing a nitrogen heterocyclic ligand were reported by Alessio (University of Trieste, Trieste, Italy). The anionic imidazole derivative, Na(tRu(DMSO)mCL4) in particular, was active against P388 leukaemia (T/C = 170) and showed some activity against platinum resistant P388 and M5076 reticulum sarcoma.
In addition to synthetic efforts, our understanding of the solution structure of platinum-DNA adducts has been increased. Patel (Columbia University, New York, USA) for example, used 2D nuclear magnetic resonance COESY and NOESY techniques to structurally characterise a complimentary dodecanucleotide duplex which contained a cis Pt(NH3)2-G-G lesion in the centre. More studies on the structural nature of Pt-DNA adducts were described by Lippard (Massachusetts Institute of Technology, Cambridge, Massachusetts, USA). These included the use of site specifically modified DNA oligonucleotides to incorporate cis GG, AG, GTG and trans GTG adducts into duplex DNA via amplification techniques. DNA bending determinations showed that the cis adducts induced bends of between 320 and 350. In addition, it was found that the cis GG and AG adducts both unwind DNA by 130, a value which correlates with repair by the bacterial (A)BC exinuclease enzyme complex.
Biochemical and molecular pharmacology
There is a large body of evidence showing that cisplatin exerts its cytotoxic effects through binding to DNA, principally through the formation of guanine-guanine and adenineguanine intra-and, to a much lesser extent, inter-strand crosslinks. Cellular resistance to cisplatin may occur via mechanisms prior to DNA binding (i.e. at the plasma membrane or cytoplasmic level) or at the level of DNA itself (Figure 3) .
Several presentations addressed the biochemistry of cisplatin transport through plasma membranes. Andrews Using clinical samples from patients receiving platinumbased chemotherapy, Reed (National Cancer Institute, Bethesda, Maryland, USA) assessed RNA for the human DNA excision repair gene ERCC1. High levels of expression in fresh tumour tissue appeared directly related to clinical resistance (P = 0.051). In one patient where levels in tumour tissue and peripheral blood were measured before treatment with carboplatin and after the development of clinical resistance, ERCC1 expression increased 10-fold in the tumour and 5-fold in white blood cells. The group suggested that ERCC1 expression may be an important marker for clinically relevant DNA repair capability. Wood (Imperial Cancer Research Fund, Potters Bar, Hertfordshire, UK) described an assay which measures the repair of cisplatin-damaged DNA in vitro by human cell extracts. Preliminary attempts to apply the assay to investigate DNA repair capacity in human tumour biopsies were described by Harris (Churchill Hospital, Oxford, UK). Further evidence for the involvement of DNA repair capacity in cisplatin resistance was described by Harrap (Institute of Cancer Research, Sutton, Surrey, UK) using a cisplatin-hypersensitive human testicular nonseminomatous germ cell line and a 6.5-fold acquired resistant variant, the removal of total platinum bound to DNA being enhanced in the resistant line. The role of oncogene expression and signal transduction pathway regulation on cisplatin sensitivity was addressed by several groups. Sklar (University of Michigan, Ann Arbor, Michigan, USA) described the modulation of resistance to cisplatin in mouse NIH3T3 fibroblasts by c-Ha-ras and c-myc oncogenes. Ras oncogene transfection significantly increased resistance to cisplatin (4.5-fold to 10-fold differences in IC50 values) as well as to ionising radiation. Using cells containing amplified c-myc sequences in either sense or antisense orientations, the group showed that cisplatin resistance correlated with c-myc levels; induction of c-myc increased cisplatin resistance by about 3-fold. Howell (UCSD, La Jolla, California, USA) showed that activiation of either the protein kinase A or protein kinase C pathways enhanced sensitivity of human ovarian 2008 cells to cisplatin by 2-to 3-fold. In contrast, and in accordance with the Sklar studies, c-Ha-ras oncogene over-expression in NIH3T3 cells (greater than 10-fold increase in p2l'r expression after 24 h) reduced cisplatin sensitivity by 8.2-fold. Scanlon (City of Hope National Medical Center, Duarte, California, USA) described studies suggesting a role for the c-fos oncogene in cisplatin resistance using a fos ribozyme (catalytic RNA) expressed in the A2780 human ovarian carcinoma cell line. However, not all studies showed such effects. Kerr (University of Glasgow, Glasgow, UK) transfected H-ras and c-myc into mink lung epithelial cells and showed no alterations in sensitivity to cisplatin.
Essigmann (Massachusetts Institute of Technology, Cambridge, Massachusetts, USA) described further studies on the recently discovered protein present in human and rodent cells that specifically binds to DNA modified with cisplatin but does not bind to inactive platinum agents (e.g. transplatin). The protein, of an apparent molecular weight of 91,000, maps to chromosome llq and binds specifically to the 1,2-intrastrand G-G and A-G adducts. Although expression has been found in many different tissues it did not correlate with cisplatin resistance in a number of human, hamster and mouse cell lines. Other such damage recognition proteins, which appear from preliminary experiments to be overexpressed in cisplatin resistant cell lines, were described by Brown (University of Glasgow, Glasgow, UK) and Chao (Chang Gung Medical College, Taoyman, Taiwan).
There was one report of the isolation of a gene associated with cisplatin resistance (Enns, UCSD, La Jolla, California, USA). Libraries were made from a human ovarian cell line (2008) and a 10-fold cisplatin resistant variant (C13) and cotransfected with PSP2-neo into Chinese hamster ovary cells. Human inserts from seven cisplatin-resistant clones were recovered using polymerase chain reaction methodology. All of the inserts were of the same size; two were sequenced revealing a sequence corresponding closely to the human mitochondrial heat shock protein 60, P1. To date, however, the gene has not been transfected back into the (2 -aminomethyl -pyrrolidine (1,1 -cyclobutanedicarboxylato) platinum II). All three have antitumour activity and low nephrotoxic potential in murine models, activity against human tumour xenografts, and partial or complete non-cross resistance against cisplatin resistant murine K562 leukaemia. In Phase I studies, including that presented by O'Dwyer (Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA), leukopenia or thrombocytopenia were the dose limiting toxicities in all instances, except in the case of continuous intravenous infusion of DWA21 14R, when emesis and diarrhoea were dose limiting. Phase II studies are ongoing in Japan. Hirabayashi (National Hospital Fukuyama, Fukuyama, Japan) reported encouraging activity of 254-S in combination with peplomycin and ifosfamide in advanced cervical cancer.
After the clinical evaluation of these eight new platinum complexes have been completed little doubt should exist as to the utility of the cisplatin resistant murine leukaemias and the 1,2-diaminocyclohexane ligand, as models of and a strategy to circumvent clinical cisplatin resistance, since seven of these new complexes lack cross resistance to cisplatin resistant murine leukaemias, and three are 1,2-diaminocyclohexane derivatives. The dicarboxylatocyclobutane substituent is a feature of four platinum complexes in clinical development. Two of these agents are associated with significant clinical nephrotoxicity which is surprising in view of the previously described relationship between leaving group stability and kidney damage. Some of the new compounds cause major non-haematological toxicities, e.g. neurotoxicity, nephrotoxicity and severe emesis, which may limit their clinical application unless unique activity is demonstrated. Interestingly, some of the new platinum complexes are unlike carboplatin in that their myelosuppression predominants against the white cell lineage rather than platelets.
Taxol, an alkaloid extracted from the Pacific Yew (Taxus brevifolia) is active in advanced and cisplatin refractory ovarian cancer, and has major toxicities that are not shared with cisplatin. The cytotoxicity of the taxol-cisplatin combination is sequence dependent, with taxol followed by cisplatin treatment sequence having the highest in vitro activity. A phase I study of this combination was reported by Rowinsky (Johns Hopkins Oncology Center, Baltimore, Maryland, USA). Neutropoenia was dose limiting and sequence dependent, being more severe with cisplatin preceding taxol. This treatment sequence was also associated with reduced taxol clearance. Other toxicities include emesis, alopecia and, in four patients, ventricular tachycardia. The recommendations for Phase II studies are the taxol before cisplatin treatment sequence and cisplatin/taxol doses of 75-135 mg m-2 with further taxol escalation if tolerable. Results of these studies are awaited with interest.
The development of ORG 2766, a neurotrophic ACTH analogue devoid of adrenocorticotrophic properties was updated by Hamers (Rudolf Magnus Institute, Utrecht, The Netherlands). This peptide's efficacy in the prophylaxis and treatment of cisplatin-induced neuropathy was first demonstrated in the rat model and its preventive action has been confirmed in ovarian cancer patients receiving cisplatin, in whom very few side effects were apparent. Experiments demonstrating the efficacy of ORG2766 during high dose cisplatin treatment were presented.
